SCHEMBL1330745

SCHEMBL1330745

CC(=O)OC[C@@H](C)C[C@@H](C)CO

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.39
ALDH1A1 P00352 4/20 0.37
LMNA P02545 2/20 0.37
HSD17B10 Q99714 1/20 0.37
SMN1; SMN2 Q16637 4/20 0.35
CHRM1 P11229 3/20 0.35
CHRM5 P08912 2/20 0.35
CHRM3 P20309 2/20 0.35
CHRM2 P08172 2/20 0.35
CHRM4 P08173 2/20 0.35
TBXA2R P21731 2/20 0.35
PGR P06401 1/20 0.35
HTR1A P08908 1/20 0.35
CHRNB2 P17787 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA7 P36544 1/20 0.35
CHRNA4 P43681 1/20 0.35
CHRNA10 Q9GZZ6 1/20 0.35
CHRNA9 Q9UGM1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1330746 1.00 TDP1 (0.39) TDP1ALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL17511777 0.89
SCHEMBL709298 0.89
SCHEMBL9756898 0.89
SCHEMBL12124735 0.83 TDP1 (0.39) TDP1ALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL12122472 0.83 ALDH1A1 (0.42) TDP1ALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL22636336 0.83 TDP1 (0.39) TDP1ALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL15542043 0.83 ALDH1A1 (0.42) TDP1ALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL15541862 0.82 TDP1 (0.42) TDP1ALDH1A1LMNAHSD17B10SMN1; SMN2
SCHEMBL9756912 0.81 TDP1 (0.48) TDP1ALDH1A1LMNAHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110282075-A1 METHOD FOR PREPARING VITTATALACTONE ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) 2011-11-17 US disclosed
US-20110282075-A1 METHOD FOR PREPARING VITTATALACTONE ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) 2011-11-17 US disclosed
US-20110282075-A1 METHOD FOR PREPARING VITTATALACTONE ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110282075-A1 METHOD FOR PREPARING VITTATALACTONE FNTA, LCAT, AAAS TDP1 4727/4885ALDH1A1 2817/4885LMNA 4629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.